항암화학요법과의 순차적, 그리고 병행적 요법으로서의 aRVS 투여로 장기 생존과 좋은 삶의 질을 유지한 전이성 비소세포폐암 증례보고
Case Report : Long-term Survival and Good-Quality of Life in Metastatic Non-small Cell Lung Cancer Patients Treated with Allergen-removed Rhus verniciflua Stokes (aRVS) as Sequential and Concurrent Treatment with Chemotherapy
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
This report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, as sequential and concurrent treatment with chemotherapy was associated with a long term survival and good quality of life in a patient with metastatic non-small cell lung cancer(NSCLC). A 51-year-old Korean female was referred to the M․μ Integrative Cancer Center, East-West Neo Medical centrer, Kyung Hee University for stage IV, metastatic NSCLC. She was treated with aRVS alone for 19 months and then received 1st line paclitaxel/carboplatin combined with aRVS, 2nd line gefitinib, and 3rd line pemetrexed. The number of cycles of pemetrexed administered was seventeen. aRVS was restarted as the 13th pemetrexed was administered. Pemetrexed with aRVS is currently ongoing. This patient has been alive for 41 months, and has been keeping a good performance status so far. We suggest aRVS as sequential and concurrent treatment with chemotherapy is an effective alternative treatment strategy.
Abstract
This report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, as sequential and concurrent treatment with chemotherapy was associated with a long term survival and good quality of life in a patient with metastatic non-small cell lung cancer(NSCLC). A 51-year-old Korean female was referred to the M․μ Integrative Cancer Center, East-West Neo Medical centrer, Kyung Hee University for stage IV, metastatic NSCLC. She was treated with aRVS alone for 19 months and then received 1st line paclitaxel/carboplatin combined with aRVS, 2nd line gefitinib, and 3rd line pemetrexed. The number of cycles of pemetrexed administered was seventeen. aRVS was restarted as the 13th pemetrexed was administered. Pemetrexed with aRVS is currently ongoing. This patient has been alive for 41 months, and has been keeping a good performance status so far. We suggest aRVS as sequential and concurrent treatment with chemotherapy is an effective alternative treatment strategy.
참고문헌 (25)
- KY Y, "Cancer control activities in the Republic of Korea", Jpn J Clin Oncol, 38, pp.327~333 (2008)
- Jemal A SR, "CA Cancer J Clin", Cancer statistics, 58, pp.71~96 (2008)
- Stinchcombe TE SM, "Considerations for second -line therapy of non-small cell lung cancer", Oncologist, 13, pp.28~36 (2008)
- Shepherd FA, "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy", J Clin Oncol, 18, pp.2095~2103 (2000)
- Schiller JH HD, "Eastern CooperativeOncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
- Mok TS WY, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Sandler A GR, "Paclitaxel -carboplatin alone or with bevacizumab for non -small-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
- Shepherd FA RPJ, "National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
- Ardizzoni A, "CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first- line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis", J Natl Cancer Inst, 99, pp.847~857 (2007)
- Hotta K, "Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer", J Clin Oncol, 22, pp.3852~3859 (2004)
- Pirker R PJ, "FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase Ⅲ trial", Lancet, 273, pp.1525~1531 (2009)
- Yoo HT RJ, "Compendium of prescriptions from the countryside(Hyangyakjipseongbang)", pp.1433~1640 (1977), Hangrimchulpansa
- 오세창, "東醫寶鑑에서 單方 민간요법이 주는 의미", 동의생리병리학회지, 20(1), pp.1~9 (2006), 대한동의병리학회
- Kook SH SY, "Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G", APOPTOSIS, 12, pp.1289~1298 (2007), SPRINGER
- 이정채, "Ethanol-eluted Extract of Rhus verniciflua Stokes Inhibits Cell Growth and Induces Apoptosis inHuman Lymphoma Cells", BMB reports, 36(4), pp.337~343 (2003), 한국생화학분자생물학회
- Lee SH, "Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized Rhus verniciflua stokes extract: a case study", Explore, 5, pp.242~244 (2009)
- "Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases", ANNALS OF ONCOLOGY, 21(6), pp.1383~269 (2010), OXFORD UNIV PRESS
- Lee SH, "Shrinkage of Gastric Cancer in an Elderly Patient Who Received Rhus verniciflua Stokes Extract", JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 16(4), pp.497~500 (2010), MARY ANN LIEBERT INC
- Kim HR, "A Case of Recurred Hepatocellular Carcinoma Refractory to Doxorubicin After Liver Transplantation Showing Response to Herbal Medicine Product, Rhus verniciflua Stokes Extract", INTEGRATIVE CANCER THERAPIES, 9(1), pp.100~104 (2010), SAGE
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Richardson MA ST, "Complementary", alternative medicine use in a comprehensive cancer center and the implications for oncology, 2000, pp.18, 2505~2514
- Socinski MA, "Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB", Ⅳ non-small- cell lung cancer, 2002, pp.20, 1335~1343
- Hanna N SF, "Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy", J Clin Oncol, 22(9), pp.1589~1597 (2004)
- Chang MH AJ, "The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer", Lung Cancer, 69, pp.323~329 (2010)
- Sun JM LK, "Efficacy and toxicity of pemetrexed as a third-line treatment for non- small cell lung cancer", Jpn J Clin Oncol, 39, pp.27~32 (2009)